CoChat

AI on Drugs: Can Artificial Intelligence Accelerate Drug Development? Evidence from a Large-Scale Examination of Bio-Pharma Firms

Lou, Bowen, Wu, Lynn · 2021 · MIS Quarterly

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.

Abstract

Advances in artificial intelligence (AI) could potentially reduce the complexities and costs in drug discovery. We conceptualize an AI innovation capability that gauges a firm’s ability to develop, manage, and utilize AI resources for innovation. Using patents and job postings to measure AI innovation capability, we find that it can affect a firm’s discovery of new drug-target pairs for preclinical studies. The effect is particularly pronounced for developing new drugs whose mechanism of impact on a disease is known and for drugs at the medium level of chemical novelty. However, AI is less helpful in developing drugs when there is no existing therapy. AI is also less helpful for drugs that are either entirely novel or those that are incremental “followon” drugs. Examining AI skills, a key component of AI innovation capability, we find that the main effect of AI innovation capability comes from employees possessing the combination of AI skills and domain expertise in drug discovery as opposed to employees possessing AI skills only. Having the combination is key because developing and improving AI tools is an iterative process requiring synthesizing inputs from both AI and domain experts during both the development and the operational stages of the tool. Taken together, our study sheds light on both the advantages and the limitations of using AI in drug discovery and how to effectively manage AI resources for drug development.

Overview

Integrity signals

Registry

Crossref · 10.25300/misq/2021/16565

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 79 references

Research works printed but not linked: 11

  1. Abrams, 2017, What’s the Value of Patent Citations? Evidence from Pharmaceuticals, Working Paper
  2. Agrawal, 2019, Artificial Intelligence, Scientific Discovery, and Commercial Innovation, Working Paper
  3. Du Plessis, 2009, Data Production Methods for Harmonized Patent Indicators: Assignee Sector Allocation
  4. Hitt, 2018, Corporate Data Literacy: Scoring Firms and Firm Performance, IHS Markit White Paper
  5. Johnson, 1990, Concepts and Applications of Molecular Similarity
  6. Jones, 2005, Growth and Ideas, 1063
  7. Marcus, 2019, Rebooting AI: Building Artificial Intelligence We Can Trust
  8. 2010, Mechanism Matters, Nature Medicine, 16, 347, 10.1038/nm0410-347) · DOI
  9. Pisano, 2006, Science Business: The Promise, the Reality, and the Future of Biotech
  10. Raymond, 2019, The AI Index 2019 Annual Report, AI Index Steering Committee, Human-Centered AI Institute, Stanford University
  11. Trafton, 2020, Artificial Intelligence Yields New Antibiotic, MIT News

Cited by

See all 178

Metadata

Authors
Lou, B., & Wu, L.
Affiliations
  • University of Connecticut (US)
  • University of Pennsylvania (US)
Venue
MIS Quarterly
Publisher
MIS Quarterly
Published
2021-09-01
Volume
45
Issue
3
Pages
1451-1482
ISSN
  • 0276-7783 (ISSN-L)
  • 2162-9730
OpenAlex
W3200787894
Cited by
177
References
78
Citations by year
2026: 53 · 2025: 58 · 2024: 34 · 2023: 19 · 2022: 10 · 2021: 3
FWCI
8.70
Type
journal article
Language
en
Open access
closed
Locations
  • MIS Quarterly (publishedVersion)
  • Journal of the Association for Information Systems (submittedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Social Sciences › Business, Management and Accounting › Strategy and Management › Innovation and Knowledge Management
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords
artificial intelligence, drug discovery, drug development, biopharmaceutical firms, AI competencies, domain knowledge, follow-on drugs, patents, job advertisements

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AI on Drugs: Can Artificial Intelligence Accelerate Drug Development? Evidence from a Large-Scale Examination of Bio-Pharma Firms. https://app.cochat.ai/papers/10.25300/misq/2021/16565
The paper
Lou, B., & Wu, L. (2021). AI on Drugs: Can Artificial Intelligence Accelerate Drug Development? Evidence from a Large-Scale Examination of Bio-Pharma Firms. MIS Quarterly. https://doi.org/10.25300/misq/2021/16565

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.